Immunovia AB

Immunovia AB
About Us
Contacts
Change country

Follow us:
Share:
Subscribe:

About Us

Immunovia AB is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer. Our first product, IMMray™ PanCan-d is the only blood test currently available specifically for the early detection of pancreatic cancer. The test has unmatched clinical performance. Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see: www.immunoviainc.com. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups globally to make this test available to all high-risk pancreatic cancer groups. The USA, the first market in which IMMray™ PanCan-d is commercially available, is the world’s largest market for the detection of pancreatic cancer with an estimated value of more than USD 4 billion annually. Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

Contacts

Immunovia AB
Medicon Village Scheelevägen 8 SE-223 63 Lund
+46 46 275 60 00
http://www.immunovia.com
info@immunovia.com

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Immunovia Publishes Report for the Third Quarter 2021

Thu, Nov 11, 2021 16:00 CET

LUND (SWEDEN) – Immunovia has today published its report for the third quarter 2021. It is available on Immunovia’s website. Patrik Dahlen, CEO: “I am very pleased that we right from the start of the commercialization of our blood test IMMray™ PanCan-d in the USA have received so much positive feedback from the pancreatic cancer community. The largest patient organization with more than 1 million constituents, Pancreatic Cancer Action Network (PanCAN), informed about our test underlining that it is the first-ever blood test specific

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

Contacts

Immunovia Publishes Report for the Third Quarter 2021

Subscribe

Media